Delcath Systems Inc (DCTH)

[guti]

they will have 11.2M left over that can be used for an acquisition,

USE OF PROCEEDS
We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $61.2 million, or $70.5 million if
the underwriters fully exercise their option to purchase additional shares, after deducting the underwriting discounts and commissions and estimated offering
expenses payable by us.
The principal purpose of this offering is to further increase our financial flexibility. We currently expect to use the net proceeds from this offering as
follows:

• approximately $30.0 million for clinical development and regulatory activities for clinical products developed from our Orascovery platform;
• approximately $10.0 million for clinical development and regulatory activities for clinical products developed from our Src Kinase Inhibition
platform;
• approximately $10.0 million for other clinical and pre-clinical research and development activities; and
• the remainder for working capital, capital expenditures and general corporate purposes.

We may use a portion of the net proceeds of this offering for the acquisition or licensing, as the case may be, of additional technologies, other assets or
businesses, or for other strategic investments or opportunities, although we have no definitive understandings, agreements or commitments to do so as of the
date hereof.